Globus Medical, Inc. (GMED) Analysts See $0.34 EPS

February 14, 2018 - By Michael Collier

 Globus Medical, Inc. (GMED) Analysts See $0.34 EPS
Investors sentiment decreased to 1.38 in 2017 Q3. Its down 0.19, from 1.57 in 2017Q2. It turned negative, as 18 investors sold Globus Medical, Inc. shares while 68 reduced holdings. 42 funds opened positions while 77 raised stakes. 64.77 million shares or 3.39% more from 62.65 million shares in 2017Q2 were reported.
Moreover, M&T Bank & Trust has 0% invested in Globus Medical, Inc. (NYSE:GMED). Segall Bryant And Hamill Limited Liability accumulated 0.22% or 319,654 shares. State Teachers Retirement System has invested 0% in Globus Medical, Inc. (NYSE:GMED). California State Teachers Retirement Sys has invested 0.01% in Globus Medical, Inc. (NYSE:GMED). Arizona State Retirement Sys invested 0.01% in Globus Medical, Inc. (NYSE:GMED). Moreover, California Employees Retirement System has 0% invested in Globus Medical, Inc. (NYSE:GMED). Schwab Charles Investment Mgmt stated it has 346,775 shares or 0.01% of all its holdings. Tudor Inv Corporation Et Al invested 0.01% of its portfolio in Globus Medical, Inc. (NYSE:GMED). 63,420 are owned by Raymond James Assocs. 9,721 were accumulated by Amalgamated Natl Bank. Ubs Asset Management Americas Inc has 206,491 shares for 0.01% of their portfolio. Alliancebernstein Ltd Partnership holds 174,111 shares. Invesco Ltd has 44,642 shares. Renaissance Tech Limited Liability Company reported 679,300 shares. Moreover, Loomis Sayles Lp has 0% invested in Globus Medical, Inc. (NYSE:GMED).

Analysts expect Globus Medical, Inc. (NYSE:GMED) to report $0.34 EPS on February, 26.They anticipate $0.03 EPS change or 9.68 % from last quarter’s $0.31 EPS. GMED’s profit would be $32.76 million giving it 33.29 P/E if the $0.34 EPS is correct. After having $0.30 EPS previously, Globus Medical, Inc.’s analysts see 13.33 % EPS growth. The stock increased 0.49% or $0.22 during the last trading session, reaching $45.28. About 283,593 shares traded. Globus Medical, Inc. (NYSE:GMED) has risen 30.88% since February 14, 2017 and is uptrending. It has outperformed by 14.18% the S&P500.

Globus Medical, Inc. (NYSE:GMED) Ratings Coverage

Among 15 analysts covering Globus Medical Inc (NYSE:GMED), 9 have Buy rating, 2 Sell and 4 Hold. Therefore 60% are positive. Globus Medical Inc had 43 analyst reports since August 3, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Bank of America on Friday, November 10. The rating was maintained by Canaccord Genuity on Thursday, August 3 with “Buy”. Wells Fargo upgraded it to “Buy” rating and $46.0 target in Monday, December 4 report. As per Wednesday, July 27, the company rating was maintained by Barclays Capital. As per Tuesday, September 19, the company rating was maintained by Canaccord Genuity. On Monday, May 16 the stock rating was downgraded by Goldman Sachs to “Sell”. The stock of Globus Medical, Inc. (NYSE:GMED) earned “Buy” rating by Canaccord Genuity on Thursday, January 4. The stock of Globus Medical, Inc. (NYSE:GMED) has “Buy” rating given on Wednesday, November 8 by Canaccord Genuity. The company was upgraded on Wednesday, April 12 by Leerink Swann. The firm has “Market Perform” rating by Leerink Swann given on Wednesday, July 27.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company has market cap of $4.36 billion. The firm offers products that address an array of spinal pathologies, anatomies, and surgical approaches. It has a 41.16 P/E ratio. It provides fusion products that are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions.

Another recent and important Globus Medical, Inc. (NYSE:GMED) news was published by Gurufocus.com which published an article titled: “Pembroke Management, LTD Buys Globus Medical Inc, Pure Storage Inc, Visteon …” on January 31, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.